FORT LAUDERDALE, Fla. — Home OCT offers personalized insights on treatment response for wet age-related macular degeneration that may help reduce treatment burden, according to a speaker.
While second-generation anti-VEGF agents allow for extended dosing intervals longer than what is on label for many patients, not all patients can be extended, Judy E. Kim, MD, FARVO, FASRS, said at the Retina World Congress.
“When a patient is switched from first generation to second generation or even within second generation, we do not know how long they can be extended, and (Read more...)